NASDAQ:BCRX
$8.01
(
0.250%
)
Friday, 26th May 2023
BioCryst Pharmaceuticals Stock Price (Quote)
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $7.28 | $9.07 | Friday, 26th May 2023 BCRX stock ended at $8.01. This is 0.25% more than the trading day before Thursday, 25th May 2023. During the day the stock fluctuated 3.71% from a day low at $7.82 to a day high of $8.11. |
| 90 days | $7.20 | $9.20 | |
| 52 weeks | $7.20 | $15.43 |
Historical BioCryst Pharmaceuticals prices
| Date | Open | High | Low | Close | Volume |
| 2023-05-26 | $8.01 | $8.11 | $7.82 | $8.01 | 2 244 012 |
| 2023-05-25 | $8.21 | $8.21 | $7.91 | $7.99 | 2 323 997 |
| 2023-05-24 | $8.78 | $8.78 | $8.15 | $8.22 | 3 000 739 |
| 2023-05-23 | $8.59 | $8.92 | $8.57 | $8.77 | 3 198 009 |
| 2023-05-22 | $8.43 | $8.62 | $8.43 | $8.57 | 2 576 675 |
| 2023-05-19 | $8.48 | $8.51 | $8.33 | $8.44 | 2 045 682 |
| 2023-05-18 | $8.49 | $8.49 | $8.27 | $8.37 | 2 031 948 |
| 2023-05-17 | $8.48 | $8.66 | $8.41 | $8.47 | 2 801 290 |
| 2023-05-16 | $8.55 | $8.55 | $8.37 | $8.46 | 2 254 687 |
| 2023-05-15 | $8.36 | $8.91 | $8.31 | $8.77 | 2 345 284 |
| 2023-05-12 | $8.37 | $8.45 | $8.25 | $8.30 | 1 832 877 |
| 2023-05-11 | $8.56 | $8.59 | $8.35 | $8.36 | 2 020 307 |
| 2023-05-10 | $8.66 | $8.82 | $8.57 | $8.63 | 1 539 373 |
| 2023-05-09 | $8.41 | $8.66 | $8.39 | $8.58 | 2 223 858 |
| 2023-05-08 | $8.54 | $8.62 | $8.42 | $8.49 | 2 588 407 |
| 2023-05-05 | $8.52 | $8.62 | $8.21 | $8.56 | 3 163 512 |
| 2023-05-04 | $8.35 | $8.52 | $8.00 | $8.47 | 3 126 234 |
| 2023-05-03 | $8.13 | $9.07 | $8.00 | $8.29 | 7 327 166 |
| 2023-05-02 | $7.50 | $7.55 | $7.28 | $7.37 | 3 328 437 |
| 2023-05-01 | $7.59 | $7.63 | $7.45 | $7.51 | 2 846 473 |
| 2023-04-28 | $7.49 | $7.67 | $7.48 | $7.61 | 1 845 637 |
| 2023-04-27 | $7.72 | $7.75 | $7.45 | $7.53 | 1 912 096 |
| 2023-04-26 | $7.48 | $7.69 | $7.42 | $7.62 | 1 942 228 |
| 2023-04-25 | $7.58 | $7.58 | $7.41 | $7.49 | 2 062 315 |
| 2023-04-24 | $7.51 | $7.61 | $7.36 | $7.61 | 2 772 736 |
| 2023-04-21 | $7.40 | $7.55 | $7.27 | $7.52 | 2 594 852 |
| 2023-04-20 | $7.39 | $7.55 | $7.27 | $7.38 | 3 213 738 |
| 2023-04-19 | $7.46 | $7.54 | $7.40 | $7.49 | 3 267 024 |
| 2023-04-18 | $7.96 | $7.97 | $7.20 | $7.50 | 6 892 984 |
| 2023-04-17 | $8.15 | $8.26 | $8.05 | $8.07 | 5 541 778 |
| 2023-04-14 | $8.38 | $8.38 | $8.00 | $8.07 | 3 674 883 |
| 2023-04-13 | $8.41 | $8.61 | $8.39 | $8.41 | 2 995 126 |
| 2023-04-12 | $8.59 | $8.62 | $8.34 | $8.34 | 1 371 089 |
| 2023-04-11 | $8.57 | $8.58 | $8.45 | $8.50 | 1 635 146 |
| 2023-04-10 | $8.61 | $8.80 | $8.37 | $8.52 | 1 862 865 |
| 2023-04-06 | $8.56 | $8.78 | $8.44 | $8.68 | 2 672 341 |
| 2023-04-05 | $8.32 | $8.58 | $8.29 | $8.53 | 2 371 358 |
| 2023-04-04 | $8.41 | $8.43 | $8.22 | $8.30 | 3 001 148 |
| 2023-04-03 | $8.31 | $8.49 | $8.23 | $8.37 | 1 935 346 |
| 2023-03-31 | $8.48 | $8.56 | $8.30 | $8.34 | 2 753 202 |
| 2023-03-30 | $8.64 | $8.71 | $8.31 | $8.39 | 2 042 406 |
| 2023-03-29 | $8.62 | $8.69 | $8.37 | $8.56 | 2 567 972 |
| 2023-03-28 | $8.43 | $8.65 | $8.35 | $8.59 | 2 047 206 |
| 2023-03-27 | $8.48 | $8.57 | $8.37 | $8.46 | 1 449 361 |
| 2023-03-24 | $8.11 | $8.57 | $8.08 | $8.50 | 2 697 700 |
| 2023-03-23 | $7.99 | $8.32 | $7.95 | $8.12 | 2 018 253 |
| 2023-03-22 | $8.16 | $8.24 | $7.92 | $7.94 | 1 951 420 |
| 2023-03-21 | $8.05 | $8.24 | $7.95 | $8.17 | 1 985 852 |
| 2023-03-20 | $8.13 | $8.13 | $7.95 | $8.01 | 2 025 911 |
| 2023-03-17 | $8.08 | $8.18 | $8.01 | $8.10 | 5 228 495 |
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II... BCRX Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
